Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review

Rui Li, Ping Zhang, Lawrence E Barker, Farah M Chowdhury, Xuanping Zhang, Rui Li, Ping Zhang, Lawrence E Barker, Farah M Chowdhury, Xuanping Zhang

Abstract

Objective: To synthesize the cost-effectiveness (CE) of interventions to prevent and control diabetes, its complications, and comorbidities.

Research design and methods: We conducted a systematic review of literature on the CE of diabetes interventions recommended by the American Diabetes Association (ADA) and published between January 1985 and May 2008. We categorized the strength of evidence about the CE of an intervention as strong, supportive, or uncertain. CEs were classified as cost saving (more health benefit at a lower cost), very cost-effective (<or=$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001 to $50,000 per LYG or QALY), marginally cost-effective ($50,001 to $100,000 per LYG or QALY), or not cost-effective (>$100,000 per LYG or QALY). The CE classification of an intervention was reported separately by country setting (U.S. or other developed countries) if CE varied by where the intervention was implemented. Costs were measured in 2007 U.S. dollars.

Results: Fifty-six studies from 20 countries met the inclusion criteria. A large majority of the ADA recommended interventions are cost-effective. We found strong evidence to classify the following interventions as cost saving or very cost-effective: (I) Cost saving- 1) ACE inhibitor (ACEI) therapy for intensive hypertension control compared with standard hypertension control; 2) ACEI or angiotensin receptor blocker (ARB) therapy to prevent end-stage renal disease (ESRD) compared with no ACEI or ARB treatment; 3) early irbesartan therapy (at the microalbuminuria stage) to prevent ESRD compared with later treatment (at the macroalbuminuria stage); 4) comprehensive foot care to prevent ulcers compared with usual care; 5) multi-component interventions for diabetic risk factor control and early detection of complications compared with conventional insulin therapy for persons with type 1 diabetes; and 6) multi-component interventions for diabetic risk factor control and early detection of complications compared with standard glycemic control for persons with type 2 diabetes. (II) Very cost-effective- 1) intensive lifestyle interventions to prevent type 2 diabetes among persons with impaired glucose tolerance compared with standard lifestyle recommendations; 2) universal opportunistic screening for undiagnosed type 2 diabetes in African Americans between 45 and 54 years old; 3) intensive glycemic control as implemented in the UK Prospective Diabetes Study in persons with newly diagnosed type 2 diabetes compared with conventional glycemic control; 4) statin therapy for secondary prevention of cardiovascular disease compared with no statin therapy; 5) counseling and treatment for smoking cessation compared with no counseling and treatment; 6) annual screening for diabetic retinopathy and ensuing treatment in persons with type 1 diabetes compared with no screening; 7) annual screening for diabetic retinopathy and ensuing treatment in persons with type 2 diabetes compared with no screening; and 8) immediate vitrectomy to treat diabetic retinopathy compared with deferred vitrectomy.

Conclusions: Many interventions intended to prevent/control diabetes are cost saving or very cost-effective and supported by strong evidence. Policy makers should consider giving these interventions a higher priority.

Figures

Figure 1
Figure 1
Selection of cost-effectiveness studies for systematic review of interventions to prevent and control diabetes.

References

    1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1–20
    1. Klonoff DC, Schwartz DM: An economic analysis of interventions for diabetes. Diabetes Care 2000;23:390–404
    1. Raikou M, McGuire A: The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003;21:543–564
    1. Zhang P, Engelgau MM, Norris SL, Gregg EW, Narayan KM: Application of economic analysis to Diabetes and Diabetes Care. Ann Intern Med 2004;140:972–977
    1. Vijgen SM, Hoogendoorn M, Baan CA, de Wit GA, Limburg W, Feenstra TL: Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics 2006;24:425–441
    1. Clarke M, Oxman AD: Cochrane Reviewers' Handbook. Oxford: updated software (October 2001), Chichester, U.K., John Wiley & Sons, Ltd;
    1. American Diabetes Association. Standards of medical care in diabetes–2009. Diabetes Care 2008;31(Suppl. 1):S12–S54
    1. Drummond MF, Jefferson TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–283
    1. Federal Reserve Bank. Foreign Exchange Rates (annual) [Internet], 2008. Available at . Accessed 30 September 2008
    1. U.S. Department of Labor. Bureau of Labor Statistics: Consumer Price Index: achieved Consumer Price Index detailed report information: U.S. city average, by medical care [Internet], 2008. Available at . Accessed 30 September 2008
    1. Laupacis A, Deeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473–481
    1. Grosse SD: Assessing cost-effectiveness in health care: history of the $50,000 per QALY threshold. Value Health 2008;8:165–178
    1. Almbrand B, Johannesson M, Sjostrand B, Malmberg K, Ryden L: Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 2000;217:33–39
    1. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE: Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993;306:1722–1725
    1. Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA: Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 2004;21:1229–1236
    1. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757–1763
    1. CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542–2551
    1. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R: UKPDS Group. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001;44:298–304
    1. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR; United Kingdom Prospective Diabetes Study. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868–877
    1. Clarke WF, Churchill DN, Forwell L, Macdonald G, Foster S: To pay or not to pay? A decision and cost-utility analysis of angiolensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ Canadian Medical Association Journal 2000;162:195–198
    1. Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A: Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clinical Therapeutics 2007;29:1508–1523
    1. Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM: Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. Pharmacoeconomics 2004;22:1015–1027
    1. Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KM, Williamson DF, Gregg E, Zhang P: Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making 2002;22(Suppl. 5):S80–S91
    1. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–744
    1. Eddy DM, Schlessinger L, Kahn R: Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251–264
    1. Elliott WJ, Weir DR, Black HR: Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 2000;160:1277–1283
    1. Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ: Cost-effectiveness of diabetes case management for low-income populations. Health Services Research 2007;42:1943–1959
    1. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660–667
    1. Gozzoli V, Palmer AJ, Brandt A, Spinas GA: Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Swiss Med Wkly 2001;131:303–310
    1. Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373–1378
    1. Grover SA, Coupal L, Zowall H, Dorais M: Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000;102:722–727
    1. Habacher W, Rakovac I, Görzer E, Haas W, Gfrerer RJ, Wach P, Pieber TR: A model to analyse costs and benefit of intensified diabetic foot care in Austria. J Eval Clin Pract 2007;13:906–912
    1. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K: Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 1999;22:1771–1778
    1. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE: Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–332
    1. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M: Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689–699
    1. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Engelgau MM: Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care 2007;30:2874–2879
    1. Javitt JC, Aiello LP, Chiang Y, Ferris FL, 3rd, Canner JK, Greenfield S: Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health-care reform. Diabetes Care 1994;17:909–917
    1. Javitt JC, Aiello LP: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164–169
    1. Jönsson B, Cook JR, Pedersen TR: The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42:1293–1301
    1. Kiberd BA, Jindal KK: Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595–1599
    1. Lindgren P, Lindström J, Tuomilehto J, Uusitupa M, Peltonen M, Jönsson B, de Faire U, Hellénius ML: DPS Study Group. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care 2007;23:177–183
    1. Maberley D, Walker H, Koushik A, Cruess A: Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. CMAJ 2003;168:160–164
    1. Mason JM, Freemantle N, Gibson JM, New JP: SPLINT trial. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care 2005;28:40–46
    1. Nicholson WK, Fleisher LA, Fox HE, Powe NR: Screening for gestational diabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies. Diabetes Care 2005;28:1482–1484
    1. Ortegon MM, Redekop WK, Niessen LW: Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care 2004;27:901–907
    1. Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G, Wenzel H, Spinas GA: The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000;43:13–26
    1. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ: An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003;18:2059–2066
    1. Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH: Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004;27:1897–1903
    1. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW: An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004;18:733–738
    1. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ: Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004;26:304–321
    1. Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, De Alvaro F: Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int Suppl 2005;93:S52–S54
    1. Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N: Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Eur J Health Econ 2007;8:161–168
    1. Palmer AJ, Valentine WJ, Ray JA: Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. Int J Clin Pract 2007;61:1626–1633
    1. Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Fuller JH: CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50:733–740
    1. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S: Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Annals of Internal Medicine 2005;143:89–99
    1. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ: Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 2005;22:1239–1245
    1. Sakthong P, Tangphao O, Eiam-Ong S, Kamolratanakul P, Supakankunti S, Himathongkam T, Yathavong K: Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology 2001;6:71–77
    1. Scuffham P, Carr L: The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586–593
    1. Segal L, Dalton AC, Richardson J: Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998;13:197–209
    1. Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM: The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001;12:230–234
    1. Shearer A, Bagust A, Sanderson D, Heller S, Roberts S: Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with type 1 diabetes in the UK. Diabet Med 2004;21:460–467
    1. Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P: RENAAL study. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabete Metab 2003;29:29–35
    1. Szucs TD, Sandoz MS, Keusch GW: The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland: an analysis of the RENAAL study. Swiss Med Wkly 2004;134:440–447
    1. Tennvall GR, Apelqvist J: Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 2001;44:2077–2087
    1. The DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409–1415
    1. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518–2523
    1. Tunis SL, Minshall ME: Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Manag Care 2008;14:131–140
    1. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720–726
    1. Vijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889–896
    1. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M: Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000;48:201–210
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–297
    1. Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J: Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230–3236
    1. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789
    1. Ackermann RT, Marrero DG: Adapting diabetes prevention program lifestyle intervention for delivery in the community. Diabetes Educ 2007;33:69.
    1. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ: Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1324–1326

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere